SEC Form 4 · accession 0001209191-17-039021
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roy Doumani
Director
Period of report
Jun 7, 2017
Accepted (ET)
Jun 9, 2017 · 9:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 7, 2017 | S | 10,000 | $84.4621 | D | 155,017 | D | |
| Common Stock | Jun 8, 2017 | S | 5,000 | $84.5268 | D | 150,017 | D | |
| Common Stock | holding | — | — | — | 25,065 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.265 to $85.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.